170 related articles for article (PubMed ID: 33901406)
1. The Future of Highly Effective Modulator Therapy in Cystic Fibrosis.
Daines CL; Morgan WJ
Am J Respir Crit Care Med; 2021 Jun; 203(12):1453-1455. PubMed ID: 33901406
[No Abstract] [Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
3. A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants.
Wainwright CE
Am J Respir Crit Care Med; 2022 Nov; 206(10):1193-1195. PubMed ID: 35856818
[No Abstract] [Full Text] [Related]
4. Therapy for cystic fibrosis--the end of the beginning?
Davis PB
N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
[No Abstract] [Full Text] [Related]
5. COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No.
Thursfield RM; Shafi N; Davies JC
Chest; 2022 Jan; 161(1):21-24. PubMed ID: 35000702
[No Abstract] [Full Text] [Related]
6. In response to "who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies".
McGarry ME; McColley SA; Taylor-Cousar J
Respir Med; 2022 Oct; 202():106953. PubMed ID: 36049345
[No Abstract] [Full Text] [Related]
7. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
Tümmler B
Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
[No Abstract] [Full Text] [Related]
8. Targeting the basic defect in cystic fibrosis.
Welsh MJ
N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
[No Abstract] [Full Text] [Related]
9. Combination CFTR modulator therapy in children and adults with cystic fibrosis.
Guimbellot JS; Taylor-Cousar JL
Lancet Respir Med; 2021 Jul; 9(7):677-679. PubMed ID: 33965001
[No Abstract] [Full Text] [Related]
10. SIMPLIFYing cystic fibrosis treatment in a post-modulator era.
Yang C
Lancet Respir Med; 2023 Apr; 11(4):299-300. PubMed ID: 36463912
[No Abstract] [Full Text] [Related]
11. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
12. Ivacaftor in a G551D homozygote with cystic fibrosis.
Harrison MJ; Murphy DM; Plant BJ
N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
[No Abstract] [Full Text] [Related]
13. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
14. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
15. A combination therapy for cystic fibrosis.
Brodsky JL; Frizzell RA
Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
[TBL] [Abstract][Full Text] [Related]
16. Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor.
Smith H; Rayment JH
Pediatr Pulmonol; 2020 Oct; 55(10):2493-2494. PubMed ID: 32678518
[No Abstract] [Full Text] [Related]
17. PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.
Fohner AE; McDonagh EM; Clancy JP; Whirl Carrillo M; Altman RB; Klein TE
Pharmacogenet Genomics; 2017 Jan; 27(1):39-42. PubMed ID: 27636560
[No Abstract] [Full Text] [Related]
18. Long-term effect of CFTR modulator therapy on airway nitric oxide.
Grasemann H; Klingel M; Avolio J; Prentice C; Gonska T; Tullis E; Ratjen F
Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31601715
[No Abstract] [Full Text] [Related]
19. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
[No Abstract] [Full Text] [Related]
20. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
Bitonti M; Fritts L; So TY
J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]